Clinical Trials Browser

INDUSTRY × Has results × Multiple Myeloma × Clear all

NCT04181827 2026-03-16

CARTITUDE-4

Phase 3 Active not recruiting

419 enrolled 10 charts

Multiple Myeloma

NCT03901963 2026-03-13

AURIGA

Phase 3 Active not recruiting

200 enrolled 12 charts

Multiple Myeloma

NCT05090566 2026-02-23

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Phase 2 Active not recruiting

46 enrolled 15 charts

Multiple Myeloma

NCT04162210 2026-02-11

DREAMM-3

Phase 3 Active not recruiting

325 enrolled 10 charts

Multiple Myeloma

NCT05014412 2026-02-10

MagnetisMM-9

Phase 2 Completed

86 enrolled 16 charts

Multiple Myeloma, Recurrence

NCT03275285 2026-02-09

IKEMA

Phase 3 Completed

302 enrolled 38 charts 1 FDA

Multiple Myeloma

NCT03215030 2026-01-29

iinnovate-1

Phase 1/2 Terminated

272 enrolled 67 charts

Multiple Myeloma

NCT05556616 2026-01-29

iinnovate-2

Phase 1 Terminated

15 enrolled 15 charts

Multiple Myeloma

NCT03246529 2026-01-15

GENESIS

Phase 3 Active not recruiting

180 enrolled 22 charts

Multiple Myeloma

NCT05228470 2026-01-06

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Phase 2 Completed

39 enrolled 15 charts

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT02362035 2025-12-11

KEYNOTE145

Phase 1/2 Completed

161 enrolled 29 charts

LymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT04649359 2025-12-02

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Phase 2 Active not recruiting

187 enrolled 14 charts 1 FDA

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03837509 2025-11-04

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Terminated

15 enrolled 15 charts

Multiple Myeloma, Recurrence

NCT04582539 2025-10-22

LIMBER

Phase 1/2 Terminated

22 enrolled 28 charts

Classical hematologyMyeloidPlasma cell

Anemia, Multiple Myeloma, Myelodysplastic Syndromes

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

137 enrolled 31 charts

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT02252172 2025-10-20

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Phase 3 Completed

737 enrolled 30 charts 1 FDA

Multiple Myeloma

NCT05064358 2025-10-07

DREAMM 14

Phase 2 Active not recruiting

177 enrolled 37 charts

Multiple Myeloma, Recurrence

NCT04191616 2025-09-04

SELECT

Phase 2 Completed

54 enrolled 17 charts

Multiple Myeloma, Recurrence

NCT03525678 2025-09-03

A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

Phase 2 Completed

221 enrolled 61 charts 2 FDA

Multiple Myeloma

NCT02136134 2025-08-29

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

498 enrolled 15 charts

Multiple Myeloma, Plasmacytoma

NCT02195479 2025-08-22

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

Phase 3 Completed

706 enrolled 29 charts

Multiple Myeloma

NCT03828292 2025-08-19

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

Phase 1 Completed

15 enrolled 91 charts

Multiple Myeloma

NCT03934684 2025-08-06

Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Phase 4 Completed

101 enrolled 11 charts

Multiple Myeloma

NCT03548207 2025-07-30

CARTITUDE-1

Phase 1/2 Completed

126 enrolled 36 charts 1 FDA

Multiple Myeloma

NCT06504524 2025-06-27

A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US

633 enrolled 15 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06956170 2025-06-11

DREAMM 8

Phase 3 Active not recruiting

21 enrolled 9 charts

Multiple Myeloma

NCT03361748 2025-05-23

KarMMa

Phase 2 Completed

149 enrolled 29 charts 1 FDA

Multiple Myeloma, Recurrence

NCT03994705 2025-05-15

Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1 Terminated

20 enrolled 12 charts

Multiple Myeloma

NCT03158688 2025-05-09

CANDOR

Phase 3 Completed

466 enrolled 33 charts 2 FDA

Multiple Myeloma

NCT06868667 2025-05-09

DREAMM 7

Phase 3 Active not recruiting

24 enrolled 10 charts

Multiple Myeloma

NCT04892446 2025-05-02

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Terminated

36 enrolled 17 charts

Multiple Myeloma

NCT02076009 2025-05-01

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

569 enrolled 18 charts

Multiple Myeloma

NCT03277105 2025-04-29

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

522 enrolled 26 charts 2 FDA

Multiple Myeloma

NCT03412565 2025-04-29

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Phase 2 Completed

265 enrolled 21 charts 3 FDA

Multiple Myeloma

NCT05347485 2025-04-25

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

Phase 2 Completed

86 enrolled 19 charts

Multiple Myeloma

NCT03871829 2025-03-30

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

Phase 2 Terminated

88 enrolled 21 charts

Multiple Myeloma

NCT03748953 2025-03-21

Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

Phase 3 Completed

37 enrolled 19 charts

Multiple Myeloma

NCT04177823 2025-03-20

A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Phase 1 Completed

6 enrolled 48 charts

Multiple Myeloma

NCT03544281 2025-03-18

DREAMM 6

Phase 1/2 Completed

153 enrolled 91 charts

Multiple Myeloma

NCT04484623 2025-03-18

DREAMM 8

Phase 3 Active not recruiting

302 enrolled 10 charts

Multiple Myeloma

NCT02924272 2025-03-12

Ixazomib Rollover Study

Phase 2 Completed

32 enrolled 13 charts

LymphoidPlasma cell

Amyloidosis, Lymphoma, Multiple Myeloma

NCT06655818 2025-03-03

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

Phase 1/2 Terminated

4 enrolled 16 charts

Multiple Myeloma

NCT02761187 2025-02-24

An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants

4,253 enrolled 21 charts

Multiple Myeloma

NCT01539083 2025-02-04

VCAT

Phase 3 Completed

256 enrolled 13 charts

Multiple Myeloma

NCT03357952 2025-02-04

A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2/3 Completed

10 enrolled 11 charts

Multiple Myeloma

NCT02990338 2025-01-17

ICARIA-MM

Phase 3 Completed

307 enrolled 32 charts 2 FDA

Multiple Myeloma

NCT04436029 2024-12-03

Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Phase 2 Completed

5 enrolled 8 charts

Multiple Myeloma

NCT02181413 2024-11-19

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

Phase 3 Completed

656 enrolled 36 charts

Multiple Myeloma

NCT05932290 2024-10-29

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma

514 enrolled 16 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04246047 2024-10-24

DREAMM 7

Phase 3 Active not recruiting

494 enrolled 10 charts 1 FDA

Multiple Myeloma